Embecta has formally completed its acquisition of UK-based medical device manufacturer Owen Mumford Holdings in a transaction valued at up to £150 million (approximately $172.6 million). The Embecta Owen Mumford acquisition, first announced in March 2026, positions the combined entity to deliver a broader suite of drug delivery and chronic care solutions to pharmaceutical partners and patients managing long-term conditions.
The transaction was structured with an upfront payment of £100 million, with up to an additional £50 million contingent on post-acquisition net sales performance of Owen Mumford’s flagship Aidaptus auto-injector platform over a three-year period. This performance-linked component underscores the strategic value placed on the Aidaptus platform and its anticipated commercial traction across multiple therapeutic areas.
The acquisition of Owen Mumford directly supports embecta’s ongoing strategic shift toward offering a broader portfolio of medical supplies, including specialised drug delivery platforms for pharmaceutical partners and products designed for patients living with chronic conditions. Embecta is specifically targeting the needs of individuals managing anaphylaxis, obesity, diabetes, and autoimmune diseases.
The deal grants embecta access to a specialised drug delivery platform capable of serving multiple therapeutic areas, while also strengthening its intellectual property portfolio most notably through ownership of the Aidaptus auto-injector platform.
The acquisition of Owen Mumford brings together two distinct areas of operational strength. Owen Mumford contributes deep expertise in device design, precision moulding, and assembly, while embecta contributes its established commercial operations and large-scale manufacturing capabilities. Together, the combined organisation is expected to expand its global market reach and improve overall operational efficiency.
Embecta currently operates with a workforce of approximately 2,500 employees and aims to supply a broad range of medical products to global markets. Owen Mumford, for its part, has built its reputation around healthcare device development, drug delivery technologies, and devices intended for chronic care and diagnostic use making the two organisations a natural operational and commercial fit.
Central to this deal is Owen Mumford’s Aidaptus auto-injector, a two-step, subcutaneous, single-use device engineered with future pharmaceutical collaborations in mind. The platform streamlines the final assembly process through a plunger rod insertion method that automatically adapts to varying fill volumes. This mechanism maintains a fixed distance between the stopper and plunger regardless of fill volume, reducing the need for additional verification steps and simplifying the manufacturing and assembly workflow.
The design of the auto-injector platform is intended to support a range of pharmaceutical partnerships across diverse therapeutic areas, offering flexibility that is increasingly sought after in the drug delivery segment.
